Last reviewed · How we verify
Misoprostol 25 µg Vaginal
At a glance
| Generic name | Misoprostol 25 µg Vaginal |
|---|---|
| Also known as | Cytotec Vagiprost PGE1 analogue |
| Sponsor | Raid M. Al-Ani |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening (PHASE3)
- Cervical Ripening With Misoprostol vs Isosorbide Mononitrate ; A Parallel -Arm Randomized Controlled Trial (NA)
- Comparison Between Vaginal Misoprostol Gel and Oral Misoprostol Solution in Induction of Labor (EARLY_PHASE1)
- Efficacy and Safety of Oral Misoprostol 25 μg vs. Vaginal Dinoprostone in Induction of Labor at Term
- A Study Comparing Vaginal Misoprostol and Intravenous Oxytocin for Induction of Labor (NA)
- Comparison Between 25 µg Vaginal Misoprostol vs Slow Release Pessary PGE2 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Misoprostol 25 µg Vaginal CI brief — competitive landscape report
- Misoprostol 25 µg Vaginal updates RSS · CI watch RSS
- Raid M. Al-Ani portfolio CI